Pharmaids Pharma Peer Comparison
BSE: 524572
₹29.64
₹-0.48
(-1.59%)
As on 15-Oct-2026 09:46IST
Market cap
₹106 Cr
Revenue (TTM)
₹25 Cr
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Edit
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
106 | 32,278 | 25,808 | 25,879 | 25,250 |
Revenue (₹ Cr) |
25 | 3,564 | 9,205 | 1,462 | 1,936 |
Net Profit (₹ Cr) |
-4.39 | 414.00 | -371.81 | 387.35 | 288.22 |
Net Margin (%) |
-17.02 | 11.23 | -3.93 | 26.01 | 14.79 |
RoE (%) |
-20.22 | 8.38 | -3.85 | 25.18 | 29.77 |
Price to Earnings |
-- | 78.92 | -- | 67.01 | 87.61 |
Price-To-Book |
2.14 | 6.41 | 3.22 | 15.00 | 18.81 |
Income Statement (₹ Cr)
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Operating Revenue
|
25.34 | 3,564.00 | 9,205.28 | 1,461.80 | 1,935.80 |
|
Total Income
|
25.79 | 3,686.00 | 9,449.59 | 1,489.25 | 1,948.58 |
|
Total Expenditure
|
34.25 | 2,792.00 | 8,195.15 | 919.25 | 1,485.56 |
|
EBITDA
|
-8.91 | 772.00 | 1,010.13 | 542.56 | 450.24 |
|
Depreciation
|
1.91 | 226.00 | 857.51 | 37.68 | 50.83 |
|
EBIT
|
-10.82 | 546.00 | 152.62 | 504.88 | 399.41 |
|
Interest
|
3.05 | 217.00 | 342.73 | 3.77 | 40.84 |
|
Other Income
|
0.45 | 122.00 | 244.31 | 27.45 | 12.78 |
|
Exceptional Items
|
6.70 | 12.00 | -216.88 | 0.00 | 0.00 |
|
Profit before Tax
|
-6.72 | 463.00 | -162.68 | 528.56 | 371.35 |
|
Provision for Tax
|
-2.33 | 49.00 | 209.13 | 141.21 | 83.14 |
|
Profit after Tax
|
-4.39 | 414.00 | -371.81 | 387.35 | 288.22 |
Liabilities (₹ Cr)
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
47.65 | 4,940.00 | 8,162.62 | 1,653.56 | 1,288.82 |
|
Minority Interest
|
-0.18 | -5.00 | 0.00 | -1.13 | 0.00 |
|
Non-Current Liabilities
|
15.65 | 1,712.00 | 5,044.14 | 42.40 | 202.03 |
|
Current Liabilities
|
24.01 | 1,622.00 | 4,758.28 | 230.82 | 835.87 |
|
Total Liabilities
|
87.26 | 8,578.00 | 17,723.32 | 1,983.96 | 2,326.71 |
Assets (₹ Cr)
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
70.05 | 5,343.00 | 10,211.52 | 1,026.85 | 519.60 |
|
Current Assets
|
10.99 | 2,606.00 | 7,191.66 | 881.27 | 1,681.81 |
|
Total Assets
|
87.26 | 8,578.00 | 17,723.32 | 1,983.96 | 2,326.71 |
|
Total Debt*
|
20.91 | 2,125.00 | 5,495.48 | 26.49 | 259.37 |
|
Net Current Assets
|
-13.02 | 984.00 | 2,433.38 | 650.46 | 845.94 |
|
Contingent Liabilities
|
-- | 768.26 | 95.72 | 17.25 | 19.09 |
Cashflow (₹ Cr)
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-4.06 | 390.00 | 1,652.60 | 292.17 | 205.05 |
|
Cash Flow from Investing Activities
|
23.34 | -241.00 | -826.03 | -265.94 | -409.72 |
|
Cash from Financing Activities
|
-19.97 | -54.00 | -38.98 | 4.10 | 283.07 |
|
Net Cash Inflow / Outflow
|
-0.69 | 95.00 | 787.59 | 30.33 | 78.39 |
Ratios
Profitability Ratios
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-15.67 | 6.79 | 1.24 | 32.42 | 29.22 |
|
ROE (%)
|
-20.22 | 8.38 | -3.85 | 25.18 | 29.77 |
|
ROA (%)
|
-4.24 | 4.94 | -2.21 | 21.93 | 24.77 |
|
EBIT Margin (%)
|
-42.69 | 15.32 | 1.66 | 34.54 | 20.63 |
|
Net Margin (%)
|
-17.02 | 11.23 | -3.93 | 26.01 | 14.79 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
18.52 | 18.37 | 0.78 | 40.90 | 46.65 |
|
EBIT Growth (%)
|
36.70 | 252.26 | -70.53 | 124.50 | 62.13 |
|
Net Profit Growth (%)
|
71.51 | 377.85 | -1,383.43 | 104.15 | 89.49 |
|
EPS Growth (%)
|
21.55 | 1,001.33 | -484.84 | 42.32 | 78.60 |
|
Book Value Growth (%)
|
-19.67 | 13.47 | 0.33 | 26.03 | 144.31 |
Valuation Ratios
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-10.55 | 81.00 | -82.48 | 67.01 | 86.26 |
|
Price / Book Value
|
2.14 | 6.41 | 3.22 | 15.00 | 18.81 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.00 | 0.08 | 0.10 |
|
EV/EBITDA
|
-14.25 | 43.71 | 29.65 | 47.33 | 55.89 |
|
Market Cap (₹ Cr)
|
97.59 | 19,071.62 | 18,108.89 | 20,944.75 | 12,753.19 |
Solvency Ratios
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.25 | 0.31 | 0.53 | 0.02 | 0.11 |
|
Short term debt to equity ratio
|
0.19 | 0.09 | 0.09 | 0.02 | 0.05 |
|
Current Ratio
|
0.46 | 1.61 | 1.51 | 3.82 | 2.01 |
|
Quick Ratio
|
0.44 | 1.06 | 0.87 | 2.82 | 1.14 |
|
Interest Coverage
|
-1.20 | 3.13 | 0.53 | 141.16 | 10.09 |
Operating Efficiency Ratios
| Pharmaids Pharma | Wockhardt | Piramal Pharma | Acutaas Chemicals | Rubicon Research | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
13.53 | 16.50 | 23.44 | 24.80 | 26.28 |
|
Asset Turnover
|
0.24 | 0.43 | 0.55 | 0.83 | 1.66 |
|
Receivable days
|
42.92 | 58.75 | 78.20 | 88.98 | 40.13 |
|
Inventory Days
|
82.44 | 75.82 | 93.30 | 56.04 | 60.29 |
|
Payable days
|
203.23 | 186.21 | 226.14 | 99.95 | 232.47 |
|
Cash Conversion Cycle
|
-77.87 | -51.64 | -54.64 | 45.07 | -132.04 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
